HOME
login
history
all enzymes
BRENDA home
History
Information on EC 3.2.1.45 - glucosylceramidase
for references in articles please use BRENDA:EC3.2.1.45Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.2.1.45 glucosylceramidaseIUBMB Comments
Also acts on glucosylsphingosine (cf. EC 3.2.1.62 glycosylceramidase).
Specify your search results
Word Map
- 3.2.1.45
- gaucher
- bone
- parkinsonism
- spleen
- marrow
- gcase
-
neuronopathic
- thrombocytopenia
-
ashkenazi
- anemia
- platelet
- dementia
-
hematological
- glycosphingolipids
- glycolipids
- visceral
- chitotriosidase
-
hepatosplenomegaly
-
splenectomy
-
non-neuronopathic
-
jewish
-
saposins
- sphingolipids
- splenomegaly
-
non-motor
-
organomegaly
-
splenectomized
- hepatomegaly
- corneum
-
4-methylumbelliferyl
-
osteonecrosis
- deoxynojirimycin
-
cytopenia
-
reticuloendothelial
- synucleinopathies
-
iminosugars
-
non-jewish
- medicine
- krabbe
-
hypersplenism
-
conduritol
- fetalis
- alpha-synuclein
- taurocholate
- sphingomyelinase
- fabry
- biotechnology
- niemann-pick
- prosaposin
- beta-glucosides
- genzyme
-
stratum
The enzyme appears in viruses and cellular organisms
Synonyms
ABG, acid beta-D-glucosidase, acid beta-glucocerebrosidase, acid beta-glucosidase, acid beta-glucosylceramidase, acid beta-glycosidase, acid glucosylceramidase, acid-beta-glucocerebrosidase, acid-beta-glucosidase, Alglucerase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
acid beta-glucocerebrosidase
acid beta-glucosidase
Alglucerase
-
-
-
-
beta-D-glucocerebrosidase
-
-
-
-
beta-glucocerebrosidase
beta-glucosidase
beta-glucosidase 2
beta-glucosylceramidase
-
-
-
-
bile acid beta-glucosidase
ceramidase, glucosyl-
-
-
-
-
ceramide glucosidase
-
-
-
-
cerebroside beta-glucosidase
-
-
-
-
Ceredase
Cerezyme
D-glucosyl-N-acylsphingosine glucohydrolase
GBA
GBA1
GBA2
Gcase
glcCer-beta-glucosidase
-
-
-
-
GlcCerase
glucocerebrosidase
glucocerebroside beta-glucosidase
-
-
-
-
glucose cerebrosidase
-
-
-
-
glucosphingosine glucosylhydrolase
-
-
-
-
glucosylceramide beta-glucosidase
glucosylcerebrosidase
-
-
-
-
glucosylsphingosine beta-D-glucosidase
-
-
-
-
glucosylsphingosine beta-glucosidase
-
-
-
-
Imiglucerase
microsomal bile acid beta-glucosidase
non-lysosomal glucosylceramidase
psychosine hydrolase
-
-
-
-
velaglucerase alfa
acid beta-glucosidase
-
-
-
-
beta-glucocerebrosidase
-
-
-
-
beta-glucocerebrosidase
-
-
D-glucosyl-N-acylsphingosine glucohydrolase
-
-
-
-
Gcase
-
-
glucocerebrosidase
-
-
-
-
glucocerebrosidase
-
-
glucosylceramide beta-glucosidase
-
-
-
-
Imiglucerase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
a D-glucosyl-N-acylsphingosine + H2O = D-glucose + a ceramide
-
-
-
-
a D-glucosyl-N-acylsphingosine + H2O = D-glucose + a ceramide
the enzyme hydrolyses the beta-glucosidic linkage of glucosylceramide with retention of anomeric conformation via a two-step, double-displacement mechanism
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of O-glycosyl bond
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
D-glucosyl-N-acylsphingosine glucohydrolase
Also acts on glucosylsphingosine (cf. EC 3.2.1.62 glycosylceramidase).
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
37228-64-1
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-glucosylceramide + H2O
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)sphingosine + D-glucose
-
-
-
-
?
12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosine
2,4-dinitrophenyl beta-D-glucopyranoside + H2O
p-nitrophenol + beta-D-glucose
-
-
-
-
?
3-amido-(Black Hole Quencher 2)-6-methoxytriazolyl-1'-ethyl-3'-amido-(boron-dipyrromethene 576/589) beta-D-glucopyranoside + H2O
3-amido-(Black Hole Quencher 2)-6-methoxytriazolyl-1'-ethyl-3'-amido-(boron-dipyrromethene 576/589) + beta-D-glucopyranose
-
-
-
-
?
3-amido-[4-[[4-(dimethylamino)phenyl]azo]-benzoic acid]-L-6-methoxytriazol-5-[(2-azidoethyl)amino]naphthalene-1-sulfonic acid beta-D-glucopyranoside + H2O
3-amido-[4-[[4-(dimethylamino)phenyl]azo]-benzoic acid]-L-6-methoxytriazol-5-[(2-azidoethyl)amino]naphthalene-1-sulfonic acid + beta-D-glucopyranose
-
-
-
-
?
4-methylumbelliferyl beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucopyranose
4-methylumbelliferyl beta-D-glucoside
4-methylumbelliferone + beta-D-glucose
-
-
-
-
?
4-methylumbelliferyl beta-D-glucoside + H2O
4-methylumbelliferone + beta-D-glucose
-
-
-
-
?
4-methylumbelliferyl glucoside + H2O
4-methylumbelliferone + D-glucose
-
-
-
-
?
4-methylumbelliferyl-beta-D-galactopyranoside + H2O
methylumbelliferone + beta-D-galactose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + beta-D-glucose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucoside + H2O
4-methylumbelliferone + beta-D-glucose
-
-
-
-
?
4-nitrophenyl beta-cellobioside + H2O
4-nitrophenol + cellobiose
1.1% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
4-nitrophenyl beta-D-glucopyranoside + H2O
4-nitrophenol + beta-D-glucopyranose
-
-
-
-
?
4-nitrophenyl beta-D-glucopyranoside + H2O
4-nitrophenol + D-glucopyranose
-
-
-
-
?
4-nitrophenyl beta-D-glucoside + H2O
4-nitrophenol + beta-D-glucose
100% activity
-
-
?
4-nitrophenyl N-acetyl-beta-D-glucosaminide + H2O
4-nitrophenol + N-acetyl-beta-D-glucosamine
0.45% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
4-nitrophenyl N-acetyl-beta-D-gucosaminide + H2O
4-nitrophenol + N-acetyl-beta-D-glucosamine
-
-
-
-
?
5-(pentafluorobenzoylamino)-fluorescein dibeta-D-glucopyranodside + H2O
5-(pentafluorobenzoylamino)-fluorescein + 2 beta-D-glucopyranose
-
-
-
-
?
5-(pentafluorobenzoylamino)fluorescein di-beta-D-glucopyranoside + H2O
5-(pentafluorobenzoylamino)fluorescein + 2 beta-D-glucopyranose
-
-
-
-
?
6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosine
6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-galactosylceramide + H2O
6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)ceramide + D-galactose
-
-
-
-
?
6-[N-methyl-N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)aminododecanoyl]sphingosyl-beta-D-glucoside + H2O
?
-
-
-
-
?
cellobiose + H2O
?
49% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
cellohexaose + H2O
?
49% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
cellotetraose + H2O
?
55% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
D-glucosyl-beta-(1-1')-N-dodecanoyl-D-erythro-sphingosine + H2O
D-glucose + N-dodecanoyl-D-erythro-sphingosine
-
product and internal standard are quantified using tandem mass spectrometry
-
-
?
gentibiose + H2O
?
8.2% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
heptylumbelliferyl-beta-D-glucopyranoside + H2O
heptylumbelliferone + glucose
-
-
-
-
?
laminaribiose + H2O
2 D-glucose
43% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
laminaripentaose + H2O
?
60% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
laminaritetraose + H2O
?
55% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
methyl beta-D-glucoside + H2O
methanol + D-glucose
0.3% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
N-(6-(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-D-erythro-glucosylsphingosine + H2O
D-glucose + N-(6-(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-sphingosine
-
-
-
-
?
n-heptyl beta-D-glucoside + H2O
heptanol + D-glucose
14% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
n-octyl beta-D-glucoside + H2O
octanol + D-glucose
13% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
N-palmitoyl-dihydroglucocerebroside + H2O
D-glucose + N-palmitoyl-dihydrocerebroside
-
-
-
-
?
N-stearoyl-dihydroglucocerebroside + H2O
D-glucose + N-stearoyl-dihydrocerebroside
-
-
-
-
?
p-nitrophenyl beta-D-glucopyranoside + H2O
p-nitrophenol + beta-D-glucose
-
-
-
-
?
sophorose + H2O
2 D-glucose
15% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
undecylumbelliferyl-beta-D-glucopyranoside + H2O
undecylumbelliferone + glucose
-
-
-
-
?
12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosine
-
-
-
-
?
12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminododecanoyl-2-N-sphingosine
-
-
-
?
3-O-benzoyl-N-stearylglucosphingosine + H2O
D-glucose + 3-O-benzoyl-N-stearylsphingosine
-
not: galactocerebroside
-
-
?
3-O-benzoyl-N-stearylglucosphingosine + H2O
D-glucose + 3-O-benzoyl-N-stearylsphingosine
-
not: galactocerebroside
-
-
?
4-methylumbelliferyl beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucopyranose
-
-
-
-
?
4-methylumbelliferyl beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucopyranose
-
-
-
?
4-methylumbelliferyl beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucopyranose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucose
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
4-methylumbelliferone + beta-D-glucose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
-
-
136450, 136452, 136453, 136456, 136459, 136462, 136464, 136465, 136470, 136471, 136473, 136475, 136476, 136477, 136478, 136479, 136483, 136484
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
-
-
-
-
?
4-methylumbelliferyl-beta-D-glucopyranoside + H2O
methylumbelliferone + glucose
-
-
-
-
?
4-nitrophenyl beta-D-galactoside + H2O
4-nitrophenol + beta-D-galactose
33% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
4-nitrophenyl beta-D-galactoside + H2O
4-nitrophenol + beta-D-galactose
33% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosine
-
NBD-glucocerebroside
-
-
?
6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosyl 1-O-beta-D-glucoside + H2O
D-glucose + 6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosine
-
complexed with bovine serum albumin
-
-
?
cellotriose + H2O
?
57% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
cellotriose + H2O
?
57% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
glucocerebroside + H2O
glucose + ceramide
-
-
-
-
?
glucocerebroside + H2O
glucose + ceramide
-
-
136450, 136452, 136453, 136456, 136458, 136459, 136462, 136463, 136464, 136465, 136466, 136469, 136470, 136471, 136473, 136474, 136475, 136476, 136477, 136478, 136479, 136483, 136484, 136486
-
-
?
glucocerebroside + H2O
glucose + ceramide
-
-
-
-
?
glucosylceramide + H2O
beta-D-glucose + ceramide
-
-
-
-
?
glucosylceramide + H2O
beta-D-glucose + ceramide
-
-
-
?
glucosylceramide + H2O
beta-D-glucose + ceramide
-
-
-
?
laminaritriose + H2O
?
59% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
laminaritriose + H2O
?
59% activity compared to 4-nitrophenyl beta-D-glucoside
-
-
?
nonylumbelliferyl-beta-D-glucopyranoside + H2O
nonylumbelliferone + glucose
-
-
-
-
?
nonylumbelliferyl-beta-D-glucopyranoside + H2O
nonylumbelliferone + glucose
-
-
-
-
?
nonylumbelliferyl-beta-D-glucopyranoside + H2O
nonylumbelliferone + glucose
-
-
-
-
?
nonylumbelliferyl-beta-D-glucopyranoside + H2O
nonylumbelliferone + glucose
-
-
-
-
?
nonylumbelliferyl-beta-D-glucopyranoside + H2O
nonylumbelliferone + glucose
-
-
-
-
?
additional information
?
-
-
the enzyme catalyses the penultimate step in the breakdown of membrane glycosphingolipids
-
-
-
additional information
?
-
-
point mutations in glucocerebrosidase can cause Gaucher disease, a common lysosomal storage disease
-
-
-
additional information
?
-
-
not: galactosylceramide, GM1a and sphingomyelin
-
-
-
additional information
?
-
the enzyme shows less than 0.04% activity with 4-nitrophenyl alpha-D-galactoside, 4-nitrophenyl alpha-L-arabinoside, 4-nitrophenyl beta-D-fucoside, 4-nitrophenyl alpha-D-glucoside, 4-nitrophenyl beta-D-mannoside, and 4-nitrophenyl beta-D-xyloside
-
-
-
additional information
?
-
-
the enzyme shows less than 0.04% activity with 4-nitrophenyl alpha-D-galactoside, 4-nitrophenyl alpha-L-arabinoside, 4-nitrophenyl beta-D-fucoside, 4-nitrophenyl alpha-D-glucoside, 4-nitrophenyl beta-D-mannoside, and 4-nitrophenyl beta-D-xyloside
-
-
-
additional information
?
-
the enzyme shows less than 0.04% activity with 4-nitrophenyl alpha-D-galactoside, 4-nitrophenyl alpha-L-arabinoside, 4-nitrophenyl beta-D-fucoside, 4-nitrophenyl alpha-D-glucoside, 4-nitrophenyl beta-D-mannoside, and 4-nitrophenyl beta-D-xyloside
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
glucocerebroside + H2O
glucose + ceramide
-
-
-
-
?
glucocerebroside + H2O
glucose + ceramide
-
-
136450, 136452, 136453, 136456, 136458, 136459, 136462, 136463, 136464, 136465, 136469, 136470, 136471, 136473, 136474, 136475, 136476, 136477, 136478, 136479, 136483, 136484, 136486
-
-
?
glucocerebroside + H2O
glucose + ceramide
-
-
-
-
?
glucosylceramide + H2O
beta-D-glucose + ceramide
-
-
-
-
?
glucosylceramide + H2O
beta-D-glucose + ceramide
-
-
-
?
glucosylceramide + H2O
beta-D-glucose + ceramide
-
-
-
?
additional information
?
-
-
the enzyme catalyses the penultimate step in the breakdown of membrane glycosphingolipids
-
-
-
additional information
?
-
-
point mutations in glucocerebrosidase can cause Gaucher disease, a common lysosomal storage disease
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1R,2S,3r,4R,5S,6s)-6-[[(1-octyl-1H-1,2,3-triazol-4-yl)methyl]amino]cyclohexane-1,2,3,4,5-pentol
-
-
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(1,3-benzodioxol-5-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(2'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholestan-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(4'-chlorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(4'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(4,6,8a,10c-tetrahydropyren-1-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5R)-octahydro-1H-2,5-methanoinden-6-ylmethoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
-
-
(2R,3S,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3S,4R,5S)-2-(hydroxymethyl)-1-[5-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(8a,10c-dihydropyren-1-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholest-5-en-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(5Z)-6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hex-5-en-1-yl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(1R,5S)-tricyclo[3.3.1.13,7]dec-2-ylmethoxy]pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3S)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
-
-
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aS,4S,5S,6S,7R,7aS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
-
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
-
(3R,4S,5S)-5-[[1-(10-hydroxydecyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
-
(3R,4S,5S)-5-[[1-(6-hydroxyhexyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
-
(3R,4S,5S,3'R,4'S,5'S)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
-
-
(3S,4R,5R)-5-([1-[6-([5-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]pentyl]oxy)hexyl]-1H-1,2,3-triazol-4-yl]methoxy)piperidine-3,4-diol
-
-
(3S,4R,5R)-5-[(1-[10-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]decyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
-
(3S,4R,5R)-5-[(1-[22-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-3,6,9,12-tetraoxadocosan-1-yl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
-
(3S,4R,5R)-5-[(1-[6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
-
(3S,4R,5R)-5-[[1-(2,5,8,11-tetraoxatridecan-13-yl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
-
(3S,4R,5R)-5-[[1-(2-[2-[2-([6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]oxy)ethoxy]ethoxy]ethyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
-
(3S,4R,5R,3'S,4'R,5'R)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
-
-
(R)-N-methyl-2-(pyridin-3-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl)quinazolin-4-amine
-
-
(S)-N-methyl-2-(pyridin-3-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl)quinazolin-4-amine
-
-
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)-3-phenylpropan-2-ol
-
-
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)propan-2-ol
-
-
1-[3-[(5-bromopyridin-2-yl)(3,4-dichlorobenzyl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]thiourea
-
-
2,2'-([4-[(5-chloro-2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]imino)diethanol
-
-
2,4-dinitrophenyl 2-deoxy-2-fluoro-beta-D-glucoside
-
2-(4-(5-chloro-2-methoxyphenylamino)-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-ylamino)ethanol
-
-
2-(pyridin-3-yl)-N-[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine
-
-
2-(pyridin-3-yl)-N-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine
-
-
2-([4-(3,3-difluoropyrrolidin-1-yl)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-(benzylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-(butylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-azetidin-1-yl-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2,4-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2,5-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)benzamide
-
-
2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
-
-
2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)acetamide
-
-
2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-nitrophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-phenoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-tert-butoxy-5-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(2-tert-butoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-methylphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(3-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-chlorophenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(4-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-benzyl-2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-(diethylamino)-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-azepan-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-piperidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
-
-
2-deoxy-2-fluoro-beta-D-glucopyranosyl-N-phenyltrifluoroacetimidate
-
semi-irreversible inhibitor
-
2-[(4-pyrrolidin-1-yl-6-[[2-(trifluoromethoxy)phenyl]amino]-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[2-(benzyloxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[2-(methylsulfanyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[(4-[[5-chloro-2-(1-methylethoxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
-
-
2-[[4-(prop-2-en-1-ylamino)-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino]ethanol
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-2-carbonitrile
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-3-carbonitrile
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-4-carbonitrile
-
-
4-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)butan-1-ol
-
-
4-benzyl-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
-
-
4-chloro-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
-
-
4-methyl-N-[4-methyl-2-(4-methylpiperidin-1-yl)quinolin-6-yl]cyclohexanecarboxamide
-
-
4-methyl-N-[4-methyl-2-(4-pyrimidin-4-ylpiperazin-1-yl)-1,2-dihydroquinolin-6-yl]cyclohexanecarboxamide
-
-
4-O-(beta-D-glucopyranosyl)-N-butyl-2-O-butyl-1,5-dideoxy-1,5-imino-D-glucitol
-
-
4-[4-(cyanomethoxy)phenyl]-4-oxo-N-{3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl}butanamide
-
-
4-[[(4-chlorophenyl)sulfonyl]amino]-N-(2,5-dihydro-1,3-thiazol-2-yl)benzamide
-
-
5-((4-methylphenyl)thio)-quinazoline 2,4-diamine
-
inhibition of wild-type enzyme and chaperone function on mutant enzyme. Treated fibroblasts from patients with Gaucher disease show decreased levels of enzyme in their endoplasmic reticulum and increased levels in lysosomes. Compound stabilizes a domain III active-site loop
5-(3,5-dichlorophenoxy)-N-(4-pyridinyl)-2-furamide
-
inhibition of wild-type enzyme and chaperone function on mutant enzyme. Treated fibroblasts from patients with Gaucher disease show decreased levels of enzyme in their endoplasmic reticulum and increased levels in lysosomes. Compound stabilizes a domain III active-site loop
methyl ([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)acetate
-
-
monoclonal antibodies
-
100% inhibition with F1 and F2, 60% inhibition with no. 61
-
N-(5-adamantane-1-yl-methoxy)pentyl-deoxynojirimycin
-
extremely potent inhibitor for GBA2
N-(5-adamantane-1-yl-methoxypentyl)deoxynojirimycin
-
most powerful inhibitor of isoform GBA2
N-(5-chloro-2-methoxyphenyl)-N'-(2-methoxyethyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-(5-chloro-2-methoxyphenyl)-N'-(furan-2-ylmethyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-(5-ethyl-1,3,4-thiadiazolidin-2-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
-
-
N-benzyl-N'-(5-chloro-2-methoxyphenyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-butyl-N'-(5-chloro-2-methoxyphenyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
-
-
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
-
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
-
N-[2-(3,6-dihydropyridin-1(2H)-yl)-4-methylquinolin-6-yl]cyclohexanecarboxamide
-
-
N-[2-(diethylamino)-4-methyl-1,2-dihydroquinolin-6-yl]-4-methylcyclohexanecarboxamide
-
-
N-[2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenyl]acetamide
-
-
N-[2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethyl]acetamide
-
-
N-[2-[(3-chlorophenyl)amino]-4-methyl-1,2-dihydroquinolin-6-yl]-4-methylcyclohexanecarboxamide
-
-
(1R,2R,3S,4S,5R,6S)-7-oxabicyclo[4.1.0]heptane-2,3,4,5-tetrol
-
-
(1R,2R,3S,4S,5R,6S)-7-oxabicyclo[4.1.0]heptane-2,3,4,5-tetrol
-
-
(1R,2R,3S,4S,5R,6S)-7-oxabicyclo[4.1.0]heptane-2,3,4,5-tetrol
-
-
conduritol B epoxide
-
isoform GBA2 is inactivated by conduritol B epoxide in a time-dependent manner. When 0.5 mM conduritol B epoxide is administered to cultured cells for 2 days, isoform GBA2 activity is reduced about 50-60%
isofagomine
-
competitive inhibition and role as a pharmacological chaperone. A hydrogen bonding network is formed between isofagomine and active site residues resulting in greater global stability and a shift in the melting curve by 15 degrees. Isofagomine enhances mutant enzyme activity in pre-treated N370S/N370S and F213L/L444P patient fibroblasts with Gaucher disease
additional information
-
not inhibited by 4-O-(beta-D-glucopyranosyl)-N-butyl-1,5-dideoxy-1,5-imino-D-glucitol
-
additional information
-
not inhibited by beta-1-C-(2,3-dihydroxypropyl)-1,5-dideoxy-1,5-imino-L-iditol
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.9fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.8fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.8fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.7fold and 1.3fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.7fold in N370S lymphoblasts from Gaucher patients
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.4fold and 1.1fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 2.1fold and 1.5fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
Gcase activity increase: 1.7fold in N370S lymphoblasts from Gaucher patients
(R)-4-(3-phenoxypiperidin-1-yl)-2-(pyridin-3-yl)quinazoline
-
50% activation at 0.00365 mM
(R)-N-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00237 mM
(S)-4-(3-phenoxypiperidin-1-yl)-2-(pyridin-3-yl)quinazoline
-
50% activation at 0.00475 mM
(S)-N-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00149 mM
2-(2-(pyridin-3-yl)quinazolin-4-yl)-2,3,4,9-tetrahydro-1H-pyrido-[3,4-b]indole
-
50% activation at 0.00427 mM
2-(furan-2-yl)-N-methyl-N-(2-phenoxyethyl)quinazolin-4-amine
-
50% activation at 0.02173 mM
2-(furan-3-yl)-N-methyl-N-(2-phenoxyethyl)quinazolin-4-amine
-
50% activation at 0.00168 mM
4-(2-(pyridin-3-yl)quinazolin-4-yl)-1,4-oxazepane
-
50% activation at 0.04414 mM
4-(2-(pyridin-3-yl)quinazolin-4-yl)-2,3,4,5-tetrahydrobenzo[f ]-[1,4]oxazepine
-
50% activation at 0.00974 mM
4-(2-benzylpiperidin-1-yl)-2-(pyridin-3-yl)quinazoline
-
50% activation at 0.0047 mM
4-(3,4-dihydroisoquinolin-2(1H)-yl)-2-(pyridin-3-yl)quinazoline
-
50% activation at 0.00223 mM
4-(3-benzylpiperidin-1-yl)-2-(pyridin-3-yl)quinazoline
-
50% activation at 0.00518 mM
4-(3-phenoxypyrrolidin-1-yl)-2-(pyridin-3-yl)quinazoline
-
50% activation at 0.00117 mM
4-(3-phenylpiperidin-1-yl)-2-(pyridin-3-yl)quinazoline
-
50% activation at 0.00466 mM
celastrol
-
significantly increases the quantity and catalytic activity of the enzyme by reducing protein degradation
dexamethasone
-
the pretreatment with dexamethasone has the effect of selectively increasing the uptake of wild-type and recombinant enzymes by the macrophages but not by the liver sinusoidal endothelial cells or hepatocyte cells in vitro, the dexamethasone pre-treatment increases the uptake of enzyme by kupffer cells and by splenic macrophages in vivo.
isofagomine
-
GlcCerase activity is enhanced in normal fibroblasts 1.3fold after treatment with 0.03 mM isofagomine for 5 days
Lubrol Px
-
activates when C12-4-nitrobenz-2-oxa-1,3-diazole labelled glucosylceramide is substrate at optimal concentration of 0.05-0.15%
N-((1H-benzo[d]imidazol-2-yl)methyl)-N-methyl-2-(pyridin-3-yl)-quinazolin-4-amine
-
50% activation at 0.00792 mM
N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00488 mM
N-(2-(benzyloxy)ethyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.01687 mM
N-(2-phenoxyethyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00156 mM
N-(2-phenoxyethyl)-N-propyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00318 mM
N-(4-ethynylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide
-
NCGC00188758
N-(benzo[c][1,2,5]thiadiazol-5-ylmethyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00184 mM
N-(benzo[d]oxazol-2-ylmethyl)-N-methyl-2-(pyridin-3-yl)-quinazolin-4-amine
-
50% activation at 0.01607 mM
N-(benzo[d]thiazol-2-ylmethyl)-N-methyl-2-(pyridin-3-yl)-quinazolin-4-amine
-
50% activation at 0.0069 mM
N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-methyl-2-(pyridin-3-yl)-quinazolin-4-amine
-
50% activation at 0.00163 mM
N-(n-butyl)deoxynojirimycin
-
other names are miglustat and Zavesca, about 20% increase of wild type enzyme activity at 0.0025 and 0.005 mM
N-(n-nonyl) deoxynojirimycin
-
1.3-1.4fold increase in activity is observed for the wild type enzyme at 0.02 mM
N-cyclohexyl-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00236 mM
N-cyclopentyl-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00636 mM
N-ethyl-N-(2-phenoxyethyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00538 mM
N-methyl-2-(pyridin-3-yl)-N-(quinoxalin-2-ylmethyl)quinazolin-4-amine
-
50% activation at 0.00163 mM
N-methyl-N-((2-methylisoindolin-5-yl)methyl)-2-(pyridin-3-yl)-quinazolin-4-amine
-
50% activation at 0.01491 mM
N-methyl-N-(1-phenoxypropan-2-yl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00752 mM
N-methyl-N-(2-phenoxyethyl)-2-(pyridin-2-yl)quinazolin-4-amine
-
50% activation at above 0.05 mM
N-methyl-N-(2-phenoxyethyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00355 mM
N-methyl-N-(2-phenoxyethyl)-2-(pyridin-4-yl)quinazolin-4-amine
-
50% activation at 0.00289 mM
N-methyl-N-(2-phenoxyethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine
-
50% activation at 0.00089 mM
N-methyl-N-(2-phenoxypropyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00897 mM
N-methyl-N-(3-phenoxypropyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00616 mM
N-methyl-N-(3-phenylpropyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00501 mM
N-methyl-N-(4-phenylbutyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00399 mM
N-methyl-N-(naphthalen-2-ylmethyl)-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.0038 mM
N-methyl-N-phenethyl-2-(pyridin-3-yl)quinazolin-4-amine
-
50% activation at 0.00139 mM
N-nonyl-deoxynojirimycin
-
Gcase activity increase: 1.9fold in N370S lymphoblasts from Gaucher patients
phosphatidylinositol
-
acidic, unsaturated phospholipid interfaces interact with acid beta-glucosidase to conform the enzyme into an active structure
sodium cholate
-
activates when C12-4-nitrobenz-2-oxa-1,3-diazole labelled glucosylceramide is substrate at concentration of optimal 0.5%
Tween 20
-
activates when C12-4-nitrobenz-2-oxa-1,3-diazole labelled glucosylceramide is substrate at optimal concentration of 0.05-0.15%
phosphatidylglycerol
-
acidic phospholipids, fatty acid composition important, higher activation in combination with heat-stable factor
phosphatidylserine
-
acidic, unsaturated phospholipid interfaces interact with acid beta-glucosidase to conform the enzyme into an active structure
saposin C
-
required for full activity reconstruction of pure enzyme, study of saposin C, acidic, unsaturated phospholipid and enzyme interaction
-
saposin C
-
optimal in vitro enzyme activity requires saposin C. Reduced saposin levels increase the instability of V394L or D409H GCases, the decreases leads to large accumulations of glucosylceramide in all tissues
-
Triton X-100
-
activates when C12-4-nitrobenz-2-oxa-1,3-diazole labelled glucosylceramide is substrate at optimal concentration of 0.05-0.15%
additional information
-
The reconstruction of the activity of lysosomal enzyme requires phospholipids and a protein factor: saposin C. The hydrophobic properties of saposin C are regulated by the pH of the environment. The interaction of saposin C with membranes is affected by the content of anionic phospholipids
-
additional information
-
isoform GBA2 requires phospholipids for optimal activity
-
additional information
-
not activated by N-(cyclopropylmethyl)-N-(2-phenoxyethyl)-2-(pyridin-3-yl)-quinazolin-4-amine, 2-(2-(pyridin-3-yl)quinazolin-4-yl)-2,3,4,5-tetrahydro-1H-pyrido-[4,3-b]indole, N-methyl-N-(2-phenoxyethyl)-2-phenylquinazolin-4-amine, N-methyl-N-(2-phenoxyethyl)-2-(thiophen-3-yl)quinazolin-4-amine, and N-methyl-N-(2-phenoxyethyl)-2-(thiophen-2-yl)quinazolin-4-amine
-
additional information
-
a lysosomal integral membrane protein type-2 helix 5-derived peptide fused to a cellpenetrating peptide can be used to activate endogenous as well as recombinant wild-type or mutant enzyme efficiently
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00204
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-galactosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.00464
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-glucosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.05
12(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexyl-2-N-sphingosyl 1-O-beta-D-glucoside
-
-
0.1445
4-methylumbelliferyl-beta-D-galactopyranoside
-
in 50 mM MES buffer, pH 6.0, at 37°C
16.3
4-nitrophenyl beta-D-galactoside
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
0.03
6(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))aminohexanoyl-2-N-sphingosyl 1-O-beta-D-glucoside
-
-
0.25
cellobiose
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
0.27
laminaribiose
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
0.0003
2,4-dinitrophenyl beta-D-glucopyranoside
-
pH 6.5, 37°C, mutant E411A
0.16
2,4-dinitrophenyl beta-D-glucopyranoside
-
pH 6.5, 37°C, wild-type enzyme
1.06
4-methylumbelliferyl beta-D-glucopyranoside
-
taliglucerase alfa, at pH 5.5 and 37°C
1.107
4-methylumbelliferyl beta-D-glucopyranoside
-
velaglucerase alfa, at pH 5.5 and 37°C
1.127
4-methylumbelliferyl beta-D-glucopyranoside
-
imiglucerase, at pH 5.5 and 37°C
0.04928
4-methylumbelliferyl-beta-D-glucopyranoside
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.862
4-methylumbelliferyl-beta-D-glucopyranoside
-
in 50 mM citric acid, KH2PO4 (pH 5.9), 10 mM sodium taurocholate, and 0.01% Tween 20, at 21°C
2.7
4-methylumbelliferyl-beta-D-glucopyranoside
-
in presence of phosphatidylserine and heat-stable factor
2.331
4-nitrophenyl beta-D-glucopyranoside
-
velaglucerase alfa, at pH 5.5 and 37°C
2.592
4-nitrophenyl beta-D-glucopyranoside
-
taliglucerase alfa, at pH 5.5 and 37°C
0.18
4-nitrophenyl beta-D-glucoside
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
0.21
4-nitrophenyl beta-D-glucoside
wild type enzyme with N-terminal tag, at pH 5.5 and 60°C
0.26
4-nitrophenyl beta-D-glucoside
mutant enzyme R544W, at pH 5.5 and 60°C
15.7
4-nitrophenyl beta-D-glucoside
mutant enzyme R786H, at pH 5.5 and 60°C
41
4-nitrophenyl beta-D-glucoside
mutant enzyme D508N, at pH 5.5 and 60°C
110
4-nitrophenyl beta-D-glucoside
mutant enzyme D508H, at pH 5.5 and 60°C
0.015
glucosylceramide
-
imiglucerase, in 50 mM sodium citrate, pH 6.0 with 0.75 mg/ml bovine serum albumin, at 37°C
0.019
glucosylceramide
-
velaglucerase alfa, in 50 mM sodium citrate, pH 6.0 with 0.75 mg/ml bovine serum albumin, at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.03
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-galactosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
0.12
(6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino]hexanoyl)-beta-D-glucosylceramide
-
in 50 mM MES buffer, pH 6.0, at 37°C
1.57
4-methylumbelliferyl-beta-D-galactopyranoside
-
in 50 mM MES buffer, pH 6.0, at 37°C
1.23
4-methylumbelliferyl-beta-D-glucopyranoside
-
in 50 mM MES buffer, pH 6.0, at 37°C
255
4-nitrophenyl beta-D-galactoside
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
44.4
cellobiose
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
41.4
laminaribiose
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
0.012
2,4-dinitrophenyl beta-D-glucopyranoside
-
pH 6.5, 37°C, mutant D223G
470
2,4-dinitrophenyl beta-D-glucopyranoside
-
pH 6.5, 37°C, wild-type enzyme
3.47
4-nitrophenyl beta-D-glucoside
mutant enzyme D508H, at pH 5.5 and 60°C
30.2
4-nitrophenyl beta-D-glucoside
mutant enzyme D508N, at pH 5.5 and 60°C
37.6
4-nitrophenyl beta-D-glucoside
wild type enzyme with N-terminal tag, at pH 5.5 and 60°C
48.2
4-nitrophenyl beta-D-glucoside
mutant enzyme R544W, at pH 5.5 and 60°C
49
4-nitrophenyl beta-D-glucoside
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
193
4-nitrophenyl beta-D-glucoside
mutant enzyme R786H, at pH 5.5 and 60°C
31.67
glucosylceramide
-
imiglucerase alfa, in 50 mM sodium citrate, pH 6.0 with 0.75 mg/ml bovine serum albumin, at 37°C
35
glucosylceramide
-
velaglucerase alfa, in 50 mM sodium citrate, pH 6.0 with 0.75 mg/ml bovine serum albumin, at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
15.6
4-nitrophenyl beta-D-galactoside
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
178
cellobiose
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
153
laminaribiose
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
0.031
4-nitrophenyl beta-D-glucoside
mutant enzyme D508H, at pH 5.5 and 60°C
0.74
4-nitrophenyl beta-D-glucoside
mutant enzyme D508N, at pH 5.5 and 60°C
12.3
4-nitrophenyl beta-D-glucoside
mutant enzyme R786H, at pH 5.5 and 60°C
179
4-nitrophenyl beta-D-glucoside
wild type enzyme with N-terminal tag, at pH 5.5 and 60°C
186
4-nitrophenyl beta-D-glucoside
mutant enzyme R544W, at pH 5.5 and 60°C
272
4-nitrophenyl beta-D-glucoside
wild type enzyme without N-terminal tag, at pH 5.5 and 60°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0003
(1R,2S,3r,4R,5S,6s)-6-(nonylamino)cyclohexane-1,2,3,4,5-pentol
-
pH and temperature not specified in the publication
0.00033
(1R,2S,3r,4R,5S,6s)-6-[[(1-octyl-1H-1,2,3-triazol-4-yl)methyl]amino]cyclohexane-1,2,3,4,5-pentol
-
pH and temperature not specified in the publication
0.0000022
(2R,3S,4S,5R)-2-octylpiperidine-3,4,5-triol
-
pH and temperature not specified in the publication
0.00001
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.000003
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0018
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0048
(3aR,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0015
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0088
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.0111
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00044
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0017
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0024
(3aRS,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0259
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00053
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.0036
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00004
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0125
(3aS,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.000002
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0028
(3aS,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00018
(3aS,4S,5S,6S,7R,7aS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.0034
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00007
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00023
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.00004
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.000002
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.000007
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
-
pH 5.2, 37°C
0.0013
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00047
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.00013
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
-
pH 5.2, 37°C
0.0000084 - 0.000025
(3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol
-
pH and temperature not specified in the publication
0.0005
(3R,4R,5S)-1-nonylpiperidine-3,4,5-triol
-
pH and temperature not specified in the publication
0.0019
(3R,4R,5S)-piperidine-3,4,5-triol
-
pH and temperature not specified in the publication
0.0000021 - 0.0000067
(3R,4S,5S)-5-[(1-nonyl-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.0000082 - 0.0000133
(3R,4S,5S)-5-[[1-(10-hydroxydecyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.00016 - 0.000341
(3R,4S,5S)-5-[[1-(6-hydroxyhexyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.0000016 - 0.0000021
(3R,4S,5S,3'R,4'S,5'S)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
0.0000278 - 0.0000289
(3S,4R,5R)-5-([1-[6-([5-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]pentyl]oxy)hexyl]-1H-1,2,3-triazol-4-yl]methoxy)piperidine-3,4-diol
0.0000199 - 0.0000216
(3S,4R,5R)-5-[(1-[10-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]decyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.0000073 - 0.0000252
(3S,4R,5R)-5-[(1-[22-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-3,6,9,12-tetraoxadocosan-1-yl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.0001642 - 0.0031
(3S,4R,5R)-5-[(1-[6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.059 - 0.144
(3S,4R,5R)-5-[[1-(2,5,8,11-tetraoxatridecan-13-yl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.00026 - 0.000391
(3S,4R,5R)-5-[[1-(2-[2-[2-([6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]oxy)ethoxy]ethoxy]ethyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.000225 - 0.137
(3S,4R,5R,3'S,4'R,5'R)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
0.0057 - 0.0069
(3S,4S,5S)-5-(hydroxymethyl)piperidine-3,4-diol
-
pH and temperature not specified in the publication
2.2
alpha-1-C-nonyl-1-deoxyimino-D-xylitol
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.0000017
(3R,4S,5S)-5-(nonyloxy)piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.0000023
(3R,4S,5S)-5-(nonyloxy)piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.0000021
(3R,4S,5S)-5-[(1-nonyl-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.0000067
(3R,4S,5S)-5-[(1-nonyl-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.0000082
(3R,4S,5S)-5-[[1-(10-hydroxydecyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.0000133
(3R,4S,5S)-5-[[1-(10-hydroxydecyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.00016
(3R,4S,5S)-5-[[1-(6-hydroxyhexyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.000341
(3R,4S,5S)-5-[[1-(6-hydroxyhexyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.0000016
(3R,4S,5S,3'R,4'S,5'S)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
-
at pH 5.2, temperature not specified in the publication
0.0000021
(3R,4S,5S,3'R,4'S,5'S)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
-
at pH 7.0, temperature not specified in the publication
0.0423
(3S,4R,5R)-5-(nonyloxy)piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.069
(3S,4R,5R)-5-(nonyloxy)piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.0000278
(3S,4R,5R)-5-([1-[6-([5-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]pentyl]oxy)hexyl]-1H-1,2,3-triazol-4-yl]methoxy)piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.0000289
(3S,4R,5R)-5-([1-[6-([5-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]pentyl]oxy)hexyl]-1H-1,2,3-triazol-4-yl]methoxy)piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.015
(3S,4R,5R)-5-[(1-nonyl-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.071
(3S,4R,5R)-5-[(1-nonyl-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.0000199
(3S,4R,5R)-5-[(1-[10-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]decyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.0000216
(3S,4R,5R)-5-[(1-[10-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]decyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.0000073
(3S,4R,5R)-5-[(1-[22-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-3,6,9,12-tetraoxadocosan-1-yl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.0000252
(3S,4R,5R)-5-[(1-[22-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-3,6,9,12-tetraoxadocosan-1-yl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.0001642
(3S,4R,5R)-5-[(1-[6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.0031
(3S,4R,5R)-5-[(1-[6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.059
(3S,4R,5R)-5-[[1-(2,5,8,11-tetraoxatridecan-13-yl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.144
(3S,4R,5R)-5-[[1-(2,5,8,11-tetraoxatridecan-13-yl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.00026
(3S,4R,5R)-5-[[1-(2-[2-[2-([6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]oxy)ethoxy]ethoxy]ethyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 7.0, temperature not specified in the publication
0.000391
(3S,4R,5R)-5-[[1-(2-[2-[2-([6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]oxy)ethoxy]ethoxy]ethyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
-
at pH 5.2, temperature not specified in the publication
0.000225
(3S,4R,5R,3'S,4'R,5'R)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
-
at pH 5.2, temperature not specified in the publication
0.137
(3S,4R,5R,3'S,4'R,5'R)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
-
at pH 7.0, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000015 - 0.0008
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0005
(2R,3R,4R,5S)-1-(5-[[4-(1,3-benzodioxol-5-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00003 - 0.00025
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000004 - 0.002
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000015 - 0.003
(2R,3R,4R,5S)-1-(5-[[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000005 - 0.003
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0003
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.00125
(2R,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0003
(2R,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00001 - 0.000125
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0003
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0004
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000004 - 0.0015
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.0003
(2R,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.4
(2R,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0006
(2R,3R,4R,5S)-1-[5-[(2'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00000008 - 0.0002
(2R,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.00025
(2R,3R,4R,5S)-1-[5-[(3'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.00000008 - 0.00025
(2R,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000005 - 0.0005
(2R,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholestan-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0005
(2R,3R,4R,5S)-1-[5-[(4'-chlorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0004
(2R,3R,4R,5S)-1-[5-[(4'-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0001 - 0.0025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
0.00000008 - 0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.00000012 - 0.0002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.00001 - 0.0008
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.00001 - 0.003
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
0.00001 - 0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
0.000025 - 0.01
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)benzyl]oxy]pentyl)piperidine-3,4,5-triol
0.000003 - 0.0005
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(4,6,8a,10c-tetrahydropyren-1-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.000001 - 0.001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.0001 - 0.01
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.000003 - 0.0006
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.0000005 - 0.00007
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.00002 - 0.0025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000002 - 0.00025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.00001 - 0.0025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxybiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000003 - 0.00025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methylbiphenyl-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000003 - 0.0015
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
0.000001 - 0.0004
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5R)-octahydro-1H-2,5-methanoinden-6-ylmethoxy]pentyl]piperidine-3,4,5-triol
0.000002 - 0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
0.00001 - 0.00006
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
0.000002 - 0.2
(2R,3S,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.0002
(2R,3S,4R,5S)-2-(hydroxymethyl)-1-[5-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]pentyl]piperidine-3,4,5-triol
0.00025
(2S,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.000001 - 0.015
(2S,3R,4R,5S)-1-[5-(8a,10c-dihydropyren-1-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.01
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.015
(2S,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.02
(2S,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.5
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.0125
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000003 - 0.02
(2S,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000006 - 0.06
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000001 - 0.01
(2S,3R,4R,5S)-1-[5-[(1R)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000002 - 0.01
(2S,3R,4R,5S)-1-[5-[(1S)-1-(biphenyl-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0000006 - 0.006
(2S,3R,4R,5S)-1-[5-[(2-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0000004 - 0.008
(2S,3R,4R,5S)-1-[5-[(3-fluorobiphenyl-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.000005 - 0.015
(2S,3R,4R,5S)-1-[5-[(3beta,17alpha,20S)-cholest-5-en-3-yloxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
0.0001 - 0.05
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
0.0000001 - 0.006
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.0000001 - 0.005
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
0.000008 - 0.012
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(5Z)-6-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]hex-5-en-1-yl]piperidine-3,4,5-triol
0.000001 - 0.05
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(naphthalen-2-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.0002 - 0.6
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-(phenanthren-9-ylmethoxy)pentyl]piperidine-3,4,5-triol
0.000002 - 0.01
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(1R,5S)-tricyclo[3.3.1.13,7]dec-2-ylmethoxy]pentyl]piperidine-3,4,5-triol
0.0000025 - 0.005
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3R)-tricyclo[3.3.1.13,7]dec-1-ylmethoxy]hexyl]piperidine-3,4,5-triol
0.00002 - 0.025
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[6-[(3S)-tricyclo[3.3.1.13,7]dec-1-yl]hexyl]piperidine-3,4,5-triol
0.00001 - 0.00004
(3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
0.000004 - 0.00001
(3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol
0.0017 - 0.006
(3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0012 - 0.0104
(3aR,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00032 - 0.0019
(3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0567 - 0.16
(3aR,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0173
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.157
(3aR,4S,5S,6S,7R,7aR)-4-(benzyloxy)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0044 - 0.0129
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00019 - 0.00071
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00054 - 0.0025
(3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0006 - 0.0029
(3aRS,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0644
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0013
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0064
(3aRS,4SR,5SR,6SR,7RS,7aRS)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.00002 - 0.00012
(3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0056 - 0.0111
(3aS,4S,5R,6S,7R,7aR)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.000005 - 0.000008
(3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0024 - 0.0068
(3aS,4S,5R,6S,7R,7aS)-3-nonyl-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00035
(3aS,4S,5S,6S,7R,7aS)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0016 - 0.0064
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00004 - 0.00022
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00008 - 0.0006
(3aSR,4SR,5RS,6SR,7RS,7aRS)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00004 - 0.0001
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(hexylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.000008 - 0.000009
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.00001 - 0.0002
(3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(octylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol
0.0039
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(hexylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.0017
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(nonylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.00074
(3aSR,4SR,5SR,6SR,7RS,7aSR)-4-(benzyloxy)-2-(octylimino)-octahydrobenzo[d]oxazole-5,6,7-triol
Homo sapiens
-
pH 5.2, 37°C
0.1
(3R,4R,5R)-5-(hydroxymethyl)-1-octylpiperidine-3,4-diol
Homo sapiens
-
pH and temperature not specified in the publication
0.000009
(3R,4S,5S)-5-(pentyloxy)piperidine-3,4-diol
Homo sapiens
-
pH and temperature not specified in the publication
0.0000043 - 0.0000048
(3R,4S,5S)-5-[(1-nonyl-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.0000199 - 0.0000243
(3R,4S,5S)-5-[[1-(10-hydroxydecyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.000182 - 0.000292
(3R,4S,5S)-5-[[1-(6-hydroxyhexyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.0000033 - 0.0000036
(3R,4S,5S,3'R,4'S,5'S)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
0.0016
(3S,4R,5R)-5-(pentyloxy)piperidine-3,4-diol
Homo sapiens
-
pH and temperature not specified in the publication
0.0000285 - 0.0000571
(3S,4R,5R)-5-([1-[6-([5-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]pentyl]oxy)hexyl]-1H-1,2,3-triazol-4-yl]methoxy)piperidine-3,4-diol
0.0000236 - 0.0000325
(3S,4R,5R)-5-[(1-[10-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]decyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.000017 - 0.000046
(3S,4R,5R)-5-[(1-[22-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-3,6,9,12-tetraoxadocosan-1-yl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.000223 - 0.0018
(3S,4R,5R)-5-[(1-[6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]-1H-1,2,3-triazol-4-yl)methoxy]piperidine-3,4-diol
0.059 - 0.129
(3S,4R,5R)-5-[[1-(2,5,8,11-tetraoxatridecan-13-yl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.000362 - 0.0011
(3S,4R,5R)-5-[[1-(2-[2-[2-([6-[4-([[(3S,4S,5R)-4,5-dihydroxypiperidin-3-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]hexyl]oxy)ethoxy]ethoxy]ethyl)-1H-1,2,3-triazol-4-yl]methoxy]piperidine-3,4-diol
0.094 - 0.162
(3S,4R,5R,3'S,4'R,5'R)-5,5'-[3,6,9,12-tetraoxadocosane-1,22-diylbis[(1H-1,2,3-triazole-1,4-diyl)methyleneoxy]]di(piperidine-3,4-diol)
0.00587
(R)-N-methyl-2-(pyridin-3-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00043
(S)-N-methyl-2-(pyridin-3-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.16
1,4-dideoxy-1,4-imino-D-arabinitol
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0023
1,5-dideoxy-1,5-iminoxylitol
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0068
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)-3-phenylpropan-2-ol
Homo sapiens
-
-
0.0207
1-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)propan-2-ol
Homo sapiens
-
-
0.00071
1-[3-[(5-bromopyridin-2-yl)(3,4-dichlorobenzyl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]thiourea
Homo sapiens
-
pH 5.9, at 22°C
0.00043 - 0.0007
2-(4-(5-chloro-2-methoxyphenylamino)-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-ylamino)ethanol
0.0000099
2-(pyridin-3-yl)-N-[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.0000087
2-(pyridin-3-yl)-N-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.0075
2-([4-(3,3-difluoropyrrolidin-1-yl)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0188
2-([4-(benzylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0061
2-([4-(butylamino)-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00231
2-([4-azetidin-1-yl-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0049
2-([4-[(2,4-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00153
2-([4-[(2,5-dimethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.02897
2-([4-[(2-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00077
2-([4-[(2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.002
2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
Homo sapiens
-
-
0.00108
2-([4-[(2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00394
2-([4-[(2-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0314
2-([4-[(2-phenoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00104
2-([4-[(2-tert-butoxy-5-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00033
2-([4-[(2-tert-butoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00669
2-([4-[(3-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00825
2-([4-[(3-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0477
2-([4-[(3-methylphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00431 - 0.00619
2-([4-[(3-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
0.0465
2-([4-[(4-chlorophenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00634 - 0.00773
2-([4-[(4-chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
0.0088
2-([4-[(4-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.01004
2-([4-[(4-methylphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00222
2-([4-[(5-benzyl-2-methoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.00096
2-([4-[(5-chloro-2-ethoxyphenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0004
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
pH 5.9, at 22°C
0.01213
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.0311
2-([4-[(5-chloro-2-methoxyphenyl)amino]-6-piperidin-1-yl-1,3,5-triazin-2-yl]amino)ethanol
Homo sapiens
-
-
0.005458
2-deoxy-2-fluoro-beta-D-glucopyranosyl-N-phenyltrifluoroacetimidate
Homo sapiens
-
at pH 5.2 and 37°C
-
0.00334
2-[(4-pyrrolidin-1-yl-6-[[2-(trifluoromethoxy)phenyl]amino]-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.02167
2-[(4-[[2-(benzyloxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.00239
2-[(4-[[2-(methylsulfanyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.00265
2-[(4-[[2-methoxy-5-(trifluoromethyl)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.00344
2-[(4-[[5-chloro-2-(1-methylethoxy)phenyl]amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl)amino]ethanol
Homo sapiens
-
-
0.01647
2-[[4-(phenylamino)-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino]ethanol
Homo sapiens
-
-
0.28
2R,5R-dihydroxymethyl-3R,4R-dihydroxypyrrolidine
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.000005 - 0.0006
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-2-carbonitrile
0.000002 - 0.0007
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-3-carbonitrile
0.000003 - 0.00035
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl]biphenyl-4-carbonitrile
0.00037
4-benzyl-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
Homo sapiens
-
-
0.00073
4-chloro-2-([4-[(2-hydroxyethyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino)phenol
Homo sapiens
-
-
0.000063
4-methyl-N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)cyclohexanecarboxamide
Homo sapiens
-
-
0.000452
4-methyl-N-(4-methyl-2-piperidin-1-ylquinolin-6-yl)cyclohexanecarboxamide
Homo sapiens
-
-
0.000268
4-methyl-N-[4-methyl-2-(4-methylpiperidin-1-yl)quinolin-6-yl]cyclohexanecarboxamide
Homo sapiens
-
-
0.00245
4-methyl-N-[4-methyl-2-(4-pyrimidin-4-ylpiperazin-1-yl)-1,2-dihydroquinolin-6-yl]cyclohexanecarboxamide
Homo sapiens
-
-
0.000075 - 0.00165
4-[4-(cyanomethoxy)phenyl]-4-oxo-N-{3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl}butanamide
0.0089
4-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]-2-(thiophen-2-yl)quinazoline
Homo sapiens
-
pH 5.9, at 22°C
0.00129
4-[[(4-chlorophenyl)sulfonyl]amino]-N-(2,5-dihydro-1,3-thiazol-2-yl)benzamide
Homo sapiens
-
-
0.1
alpha-1-C-butyl-1-deoxynojirimycin
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.000019
alpha-1-C-hexyl-1-deoxyimino-D-xylitol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.0042
alpha-1-C-hexyl-1-deoxynojirimycin
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.00056
alpha-1-C-propyl-1-deoxyimino-D-xylitol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.4
alpha-1-C-propyl-1-deoxynojirimycin
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.147
beta-1-C-butyl-1,5-dideoxy-1,5-imino-L-iditol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.043
beta-1-C-hexyl-1,5-dideoxy-1,5-imino-L-iditol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.487
beta-1-C-propyl-1,5-dideoxy-1,5-imino-L-iditol
Homo sapiens
-
in 0.15 M citrate-phosphate buffer (pH 5.5), 1% sodium taurocholate/Triton X-100, at 37°C
0.0031
calystegine A3
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.031
calystegine A5
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0025
calystegine B1
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.001
calystegine B2
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.076
calystegine B3
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.082
calystegine B4
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.0025
calystegine C1
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.019
castanospermine
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.00188
N-(1-phenoxypropan-2-yl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.0000083
N-(2,3-dihydro-1H-inden-2-yl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00214
N-(2,3-dihydro-1H-inden-2-yl)-N-methyl-2-(pyridin-3-yl)-quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.0344
N-(2,5-dihydro-1,3-thiazol-2-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.0073
N-(2-(benzyloxy)ethyl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00424
N-(2-phenoxypropyl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00097
N-(2-phenylethyl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00254
N-(3-phenoxypropyl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00178
N-(3-phenylpropyl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.000133
N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)-4-propylcyclohexanecarboxamide
Homo sapiens
-
-
0.000031
N-(4-methyl-2-morpholinoquinolin-6-yl)cyclohexanecarboxamide
Homo sapiens
-
-
0.00128
N-(4-phenylbutyl)-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.0001
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-[(phenylsulfonyl)amino]benzamide
Homo sapiens
-
pH 5.9, at 22°C
0.00296
N-(5-ethyl-1,3,4-thiadiazolidin-2-yl)-4-[methyl(phenylsulfonyl)amino]benzamide
Homo sapiens
-
-
0.27
N-butyl-1-deoxynojirimycin
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-glucopyranoside as substrate
0.044
N-butyl-isofagomine
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.00777
N-butyl-N'-(5-chloro-2-methoxyphenyl)-6-pyrrolidin-1-yl-1,3,5-triazine-2,4-diamine
Homo sapiens
-
-
0.002
N-butyldeoxynojirimycin
Homo sapiens
-
in 50 mM citrate buffer with 0.25% (v/v) Triton X-100 (pH 4.5)
0.00994
N-cycloheptyl-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00838
N-cyclooctyl-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine
Homo sapiens
-
at pH 5.0 and 25°C
0.00005
N-dodecyl-1-deoxynojirimycin
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.32
N-methyl-calystegine B2
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.000009 - 0.0005
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
0.000015 - 0.04
N-[(3R)-tricyclo[3.3.1.13,7]dec-1-yl]-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
0.00003
N-[2-(3,6-dihydropyridin-1(2H)-yl)-4-methylquinolin-6-yl]cyclohexanecarboxamide
Homo sapiens
-
pH 5.9, at 22°C
0.00106
N-[2-(diethylamino)-4-methyl-1,2-dihydroquinolin-6-yl]-4-methylcyclohexanecarboxamide
Homo sapiens
-
-
0.028
nojirimycin bisulfite
Homo sapiens
-
in 0.1 M citrate buffer (pH 5.2), using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate
0.000015
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.0008
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)biphenyl-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000002
(2R,3R,4R,5S)-1-(5-[[4-(1,3-benzodioxol-5-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.0005
(2R,3R,4R,5S)-1-(5-[[4-(1,3-benzodioxol-5-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.00003
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.00025
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000004
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.002
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000015
(2R,3R,4R,5S)-1-(5-[[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.003
(2R,3R,4R,5S)-1-(5-[[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000005
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.003
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)benzyl]oxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000001
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.0003
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000003
(2R,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.00125
(2R,3R,4R,5S)-1-[5-(biphenyl-2-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000002
(2R,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.0003
(2R,3R,4R,5S)-1-[5-(biphenyl-3-ylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.00001
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication
0.000125
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA1, pH and temperature not specified in the publication
0.000001
(2R,3R,4R,5S)-1-[5-(biphenyl-4-ylmethoxy)-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
isoform GBA2, pH and temperature not specified in the publication